Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting

被引:9
作者
Klok, RM
Arents, NLA
de Vries, R
Thijs, JC
Brouwers, JRBJ
Kleibeuker, JH
Postma, MJ
机构
[1] Univ Groningen, Inst Drug Explorat, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, Groningen, Netherlands
[2] Univ Groningen, Med Ctr, Dept Med Microbiol, Groningen, Netherlands
[3] Bethesda Hosp, Dept Internal Med, Hoogeveen, Netherlands
[4] Univ Groningen, Med Ctr, Dept Gastroenterol, Groningen, Netherlands
关键词
dyspepsia; Helicobacter pylori; management strategies; cost-effectiveness;
D O I
10.1016/j.clinthera.2005.10.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In western European countries, most dyspeptic patients are initially managed by their general practitioners (GPs), who use a range of strategies to manage dyspepsia. We performed an economic analysis of a Helicobacter pylori test-and-treat strategy versus a prompt endoscopy approach in a primary care setting. Methods: Data were used from the Strategy: Endoscopy versus Serology (SENSE) study, performed in The Netherlands from 1998 to 2001. Patients were randomized to a prompt endoscopy (n = 105) or test-and-treat (n = 118) group. Follow-up lasted I year. Adverse events were not recorded in the SENSE study. Health care costs were based on the total amount of dyspepsia-related drugs used, the number of dyspepsia-related GP visits, the number of diagnostic tests, and the number of dyspepsia-related referrals to specialists. The use of medical resources was calculated as standardized costs for 1999, recorded as euros. (On December 31, 1999, Euro1.00 = US $1.00.) Quality of life was measured at inclusion and 1 year later, using the RAND-36 questionnaire. To calculate quality-adjusted life-years (QALYs), we transformed the individual scores of the RAND-36 into I overall score, the Health Utilities Index Mark 2, which introduced a limitation to the study. An incremental cost-effectiveness ratio (ICER) was calculated. The 95% confidence limits were calculated using a parametric bootstrap method with angular transformation. All cost data were analyzed from a third-party payer perspective. Results: The total costs per patient were Euro511, with 0.037 QALY gained per patient, in the test-and-treat group, and Euro748, with 0.032 QALY gained per patient, in the endoscopy group (between groups, P < 0.001 and P = NS, respectively). The point estimate of the ICER indicated that the test-and-treat strategy yielded cost savings and QALYs gained. Parametric bootstrap confidence limits indicated cost savings per QALY gained in 75.7% of the bootstrap simulations. Conclusion: This analysis of data from the SENSE study suggests that the H pylori test-and-treat strategy was more cost-effective than prompt endoscopy in the initial management of dyspepsia in general practice, from the perspective of a third-party payer.
引用
收藏
页码:1647 / 1657
页数:11
相关论文
共 49 条
  • [11] DAMMANN HG, 1993, ALIMENT PHARM THERAP, V7, P17
  • [12] Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care
    Delaney, BC
    Wilson, S
    Roalfe, A
    Roberts, L
    Redman, V
    Wearn, A
    Hobbs, FDR
    [J]. BRITISH MEDICAL JOURNAL, 2001, 322 (7291): : 898 - 901
  • [13] DELANEY BC, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001961
  • [15] Randomised controlled trial of four dyspepsia management strategies in primary care with 12 months follow-up.
    Duggan, A
    Elliot, C
    Tolley, K
    Whynes, D
    Hawkey, CJ
    Logan, RF
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A438 - A438
  • [16] Ebell MH, 1997, J FAM PRACTICE, V44, P545
  • [17] 1977 RIETZ LECTURE - BOOTSTRAP METHODS - ANOTHER LOOK AT THE JACKKNIFE
    EFRON, B
    [J]. ANNALS OF STATISTICS, 1979, 7 (01) : 1 - 26
  • [18] *FAQ, SF36 WEB SIT
  • [19] ALTERNATIVE MANAGEMENT STRATEGIES FOR PATIENTS WITH SUSPECTED PEPTIC-ULCER DISEASE
    FENDRICK, AM
    CHERNEW, ME
    HIRTH, RA
    BLOOM, BS
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 123 (04) : 260 - 268
  • [20] The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies
    Furlong, WJ
    Feeny, DH
    Torrance, GW
    Barr, RD
    [J]. ANNALS OF MEDICINE, 2001, 33 (05) : 375 - 384